跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 19 条关于
“3SBIO”
全部
19
临床试验
0
药物
4
机构
2
资讯
13
去年
Pfizer Enters $6 Billion Licensing Deal with China's 3SBio for Novel Cancer Drug
去年
Pfizer Strikes $6 Billion Deal with 3SBio as RemeGen Raises HK$796 Million in Premium Placement
10个月前
Pfizer Accelerates PF-08634404 Bispecific Development with Multiple Phase 3 Trials Following $1.25B 3SBio Deal
3个月前
Abbisko Teams Up With Eli Lilly in Up to $1.9 Billion Oncology Drug Discovery Collaboration
7个月前
Pfizer Reports Strong Q2 2025 Performance with Pipeline Advances and Raised Guidance
3个月前
2026 China NRDL Negotiations: Record Submissions, Pre-Approval Access, and the Rise of ADCs, CAR-T, and Bispecific Antibodies
9个月前
Pfizer Allocates $6 Billion for Strategic Acquisitions in Internal Medicine and Immunology Following Metsera Deal
去年
Global Pharma Investment in China Surges to $48.5 Billion in First Half of 2025, Doubling 2024 Total
5个月前
DualityBio Achieves Phase 3 Success with Lead ADC Candidate, Advances Global Pipeline Across Multiple Cancer Types
6个月前
XellSmart Secures Fourth Consecutive FDA and NMPA Approval for iPSC Cell Therapy Targeting Rare Neurodegenerative Disease MSA-P
第 1 页,共 2 页
上一页
下一页